Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction by Shrivastava, Amit Kumar et al.
EXCLI Journal 2015;14:517-526 – ISSN 1611-2156 
Received: November 13, 2014, accepted: March 27, 2015, published: April 10, 2015 
 
 
517 
Original article: 
SERIAL MEASUREMENT OF LIPID PROFILE AND  
INFLAMMATORY MARKERS IN PATIENTS WITH  
ACUTE MYOCARDIAL INFARCTION 
 
Amit Kumar Shrivastava1*, Harsh Vardhan Singh2, Arun Raizada3, Sanjeev Kumar Singh4 
 
1 Department of Biochemistry, Sudha Rustagi College of Dental Sciences & Research,  
Faridabad, India 
2 Department of Biochemistry, North Delhi Municipal Corporation Medical College & Hindu 
Rao Hospital, Delhi, India 
3 Department of Pathology and Laboratory Medicine, Medanta-The Medicity, Gurgaon, India 
4 Department of Biochemistry, G. R. Medical College, Gwalior, India 
 
* Corresponding author: Dr. Amit Kumar Shrivastava, Department of Biochemistry, Sudha 
Rustagi College of Dental Sciences and Research, Faridabad, 121002, India. 
Contact No. +91 9971820482, Fax : +91129 – 4230010; E-mail: amitbc83@gmail.com 
 
 
http://dx.doi.org/10.17179/excli2014-671 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/). 
 
 
 
ABSTRACT 
Serum concentration of lipids and lipoproteins changes during the course of acute coronary syndrome as a con-
sequence of the inflammatory response. The objective of this study was to evaluate the effect of acute myocardi-
al infarction (AMI) on the levels of lipid profile and inflammatory markers. We investigated 400 patients with 
AMI who were admitted within 24 h of onset of symptoms. Serum levels of total cholesterol (TC), triglyceride 
(TG), low density lipoprotein (LDL) and high density lipoprotein (HDL) were determined by standard enzymatic 
methods along with high sensitive C-reactive protein (hs-CRP) (latex enhanced immunoturbidimetric assay) and 
cytokines, interleukin (IL)-6 and IL-10 (quantitative ‘‘sandwich’’ enzyme-linked immunosorbent assay). The re-
sults indicate a trend of reduced TC, LDL, and HDL, and elevated TG levels, along with pro- and anti-
inflammatory markers (p < 0.001), between day 1 and the day 2 serum samples of AMI patients. However, cor-
rections in the serum levels have been observed at day 7. Our results demonstrate significant variations in the 
mean lipid levels and inflammatory markers between days 1, 2 and 7 after AMI. Therefore, it is recommended 
that the serum lipids should be assessed within 24 hours after infarction. Early treatment of hyperlipidemia pro-
vides potential benefits. Exact knowledge regarding baseline serum lipids and lipoprotein levels as well as their 
varying characteristics can provide a rational basis for clinical decisions about lipid lowering therapy.  
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INTRODUCTION 
For many years, the proclamation that 
coronary heart disease (CHD) was not at-
tributable to traditional risk factors in up to 
50 % of cases was finally submerged after 
careful and detailed re-analysis (Miller, 
2008). Dyslipidemia is still a major risk fac-
tor for CHD. Epidemiological studies have 
conclusively linked high levels of total cho-
lesterol (TC) and low-density lipoprotein 
cholesterol (LDL-C) and low levels of high-
density lipoprotein cholesterol (HDL-C) with 
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CHD incidence and mortality (Yokokawa et 
al., 2011). It is well known that early treat-
ment of hyperlipidemia following acute my-
ocardial infarction (AMI) provides potential 
benefits and reduces the morbidity and mor-
tality of CHD. However, the levels of lipid 
and lipoproteins change during acute illness-
es that cause delay in treatment choice 
(Balci, 2011). During tissue necrosis, acute 
phasic changes occur that alter the lipid pro-
file levels post acute coronary events. Modi-
fications of serum lipids after AMI include 
reductions in TC, LDL and HDL, in the 
range of 10 - 20 %, with reciprocal increases 
in triglyceride (TG) approximating 20 - 30 % 
(Miller, 2008). Several mechanisms account-
ing for these changes include the acute phase 
response associated with up-regulation of 
LDL-receptor (R) activity and reduction in 
several pivotal HDL regulatory proteins. 
From many clinical studies it is clear that 
phasic changes do occur in patients follow-
ing AMI and therefore there is a recommen-
dation for detection of hyperlipidemia in pa-
tients with AMI that the serum lipids should 
be assessed either within 24 hours after in-
farction or after 2-3 months of AMI (Nigam, 
2007). Accurate knowledge of baseline lipid 
levels may affect the initiation of lipid-
lowering therapy, the selection of a specific 
statin and its dosage, and recognition of the 
potential need for adjunctive lipid therapy, 
and may influence the patient’s willingness 
to adhere to a recommendation for long-term 
lipid-lowering therapy (Pitt et al., 2008). 
Besides alterations in the lipoproteins, 
acute-phase response is also associated with 
changes in serum concentration of inflamma-
tory markers. There is an intra-cardiac in-
flammatory response in AMI that appears to 
be the result of the evolution of myocardial 
necrosis, as shown by higher C-reactive pro-
tein (CRP) and interleukin (IL)-6 levels in 
patients with major adverse cardiac events 
(Raposeiras Roubin et al., 2013). Several 
population based prospective studies of CHD 
have reported a close association of subtle, 
prolonged increases in baseline high sensi-
tive (hs)-CRP levels with cardiovascular risk 
(Casas et al., 2008). The majority of authors 
concur in that the admission hs-CRP concen-
tration reflects the baseline inflammatory sta-
tus of the patient; thus, patients with AMI 
and high hs-CRP levels at admission usually 
experience more cardiovascular complica-
tions during follow-up (Bursi et al., 2007). 
IL-6 is a multifunctional cytokine regulating 
humoral and cellular responses and playing a 
central role in inflammation and tissue inju-
ry. Similarly to CRP, whose synthesis is 
stimulated by IL-6, high circulating concen-
trations of IL-6 are associated with increased 
risk of cardiovascular events (Swerdlow et 
al., 2012). On the other hand, IL-10 is a cen-
trally operating anti-inflammatory cytokine 
that plays a crucial role in the regulation of 
the innate immune system and can suppress 
the production of a variety of proinflamma-
tory molecules (Biswas et al., 2010). The ex-
pression of IL-10 has been demonstrated in 
both coronary arteries and atherosclerotic 
plaque. Furthermore, serum levels of IL-10 
have been shown to be greater in individuals 
with atherosclerosis compared to controls, 
suggesting IL-10, as an anti-inflammatory 
molecule, may be elevated in response to the 
pro-inflammatory environment of atheroscle-
rosis (Lakoski et al., 2008). 
The main aim of the present study was to 
examine the changes in serum lipid profile in 
AMI patients in different time intervals. To 
analyze the association of lipid profile with 
inflammation followed by acute coronary 
events, we also estimated the levels of in-
flammatory markers hs-CRP and IL-6 along 
with anti-inflammatory marker IL-10. 
 
MATERIAL AND METHODS 
A total of 520 patients with suspected 
AMI consecutively admitted to emergency 
department in which 400 patients with con-
firmed AMI were recruited from the coro-
nary care unit and cardiology department of 
a tertiary care hospital in Gurgaon, India. We 
included patients if they met all the follow-
ing criteria: (a) all patients had AMI at base-
line; (b) blood sample for lipid profile and 
inflammatory markers estimation was ob-
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tained within 24 h from the onset of symp-
toms. Individuals with rheumatic disease, 
chronic liver diseases, renal disorders, can-
cer, sepsis and patient critically ill with less 
than one month duration infectious diseases 
and surgical procedure in 3 month duration, 
AMI and stroke within the past six months, 
severe congestive heart failure or cardiogenic 
shock, regular or chronic use of anti-
inflammatory drugs in the previous two 
months were excluded from the study. 
Clinical history and physical examination 
data, focusing on characteristics of chest pain 
and presence of cardiovascular risk factors 
were recorded for every patient. Serial elec-
trocardiograms and cardiac enzymes were al-
so obtained in all patients. MI was defined 
by detection of rise in cardiac biomarkers of 
necrosis (cTroponin I) with at least 1 value 
above the 99th percentile upper reference 
limit, together with evidence of myocardial 
ischemia with at least 1 of the following: 
electrocardiographic changes indicative of 
new ischemia (new ST-T changes or new left 
bundle branch block), new pathological Q 
waves in at least 2 contiguous leads, imaging 
evidence of new loss of viable myocardium, 
or new wall motion abnormality (Thygesen 
et al., 2007). Diabetes was defined as a pre-
vious diagnosis, use of anti-diabetic medi-
cines, or a fasting venous blood glucose level 
≥ 126 mg/dL. Hypertension was defined as 
patient systolic blood pressure > 140 mmHg 
and/or diastolic blood pressure > 90 mmHg 
at rest, over a series of repeated measure-
ments, or on treatment with antihypertensive 
medications. Body mass index (BMI) was 
calculated as weight (kg) divided by the 
square of height (m2) and a patient with a 
value above 30 was categorized as obese. 
Level of TC more than 200 mg/dL was used 
for the identification of hypercholesterole-
mia. 150 controls were also selected from 
blood donor, hospital staff and from the 
health check up individuals who met the 
matching criteria of age, sex, and smoking 
status. These healthy controls were screened 
for diabetes, hypertension and dyslipidemia. 
Subjects were informed about the study in 
detail and written consent of patients was al-
so taken before starting the study. All ethical 
measures were taken prior to start the study. 
Serum lipid profile along with inflamma-
tory markers was measured only on the fast-
ing blood samples within the first 24 h of the 
onset of symptoms of MI and again at day 2 
and day 7 post-MI. Serum TC, TG, HDL-C 
and LDL-C levels were measured by an en-
zymatic colorimetric method using reagents 
of VITROS chemistry products on automat-
ed clinical chemistry analyzers. Serum levels 
of hs-CRP were determined by latex en-
hanced immunoturbidimetric assay with the 
use of reagents and calibrators from Roche 
diagnostics. The levels of IL-6 and IL-10 
were estimated by means of commercially 
available quantitative “sandwich” enzyme-
linked immunosorbent assay (ELISA) kits 
obtained from R&D Systems, according to 
the instructions of the manufacturer. 
Statistical Package for the Social Scienc-
es 21 (SPSS 21) was used for all statistical 
analyses. All the descriptive variables were 
expressed as the mean ± standard deviation 
(SD). Independent sample t-tests were used 
to compare the mean values of variables be-
tween the AMI and control groups, whereas 
chi-square test was used for association be-
tween two categorical variables. To evaluate 
the association between serum samples of 
day 1, day 2 and day 7, the mean values were 
compared by one way analysis of variance 
(ANOVA) followed by Tukey’s post hoc 
test. A probability value p < 0.05 was con-
sidered statistically significant. 
 
RESULTS 
Table 1 shows the baseline clinical and 
laboratory characteristics of study partici-
pants. The mean age of 400 patients with 
AMI was 59.07 ± 7.34 years and the patient 
group was comprised of 155 females and 
245 males, whereas, mean age of 150 
healthy controls was 59.48 ± 7.73 years and 
it was comprised of 57 females and 93 males 
(both the groups have a same sex distribution 
ratio). The proportion of hypertension was 
42 % and diabetes mellitus was 25 % for 
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AMI patients. 140 and 85 AMI patients had 
already diagnosed hypertension and diabetes, 
respectively, whereas 32 (hypertension) and 
13 (diabetes) patients were diagnosed during 
their investigations in the hospital. There 
were no significant differences between AMI 
patients and controls in terms of age, gender, 
diabetes, hypertension, smoking and drink-
ing habits.  
Table 2 shows mean values and SD of all 
parameters studied in both groups with test 
of significance using SPSS 21 statistical 
software. Baseline serum levels of TC 
(174.81 ± 24.14 vs. 169.35 ± 16.34 mg/dL, 
p = 0.003), TG (157.51 ± 45.67 vs. 149.65 ± 
27.18 mg/dL, p = 0.014) and LDL-C (111.35 
± 25.81 vs. 105.55 ± 30.39 mg/dL, 
p = 0.039) were significantly higher in AMI 
patients as compared to the controls, whereas 
HDL-C was significantly higher (43.14 ± 
11.34 vs. 49.21 ± 9.14 mg/dL, p < 0.001) in 
the latter group. Inflammatory markers hs-
CRP (9.82 ± 5.63 vs. 1.03 ± 0.67 mg/L), and 
IL-6 (50.80 ± 25.12 vs. 14.81 ± 6.65 pg/mL) 
were found to be significantly higher 
(p < 0.001) and IL-10 (11.65 ± 8.95 vs. 
13.92 ± 6.06 pg/mL, p = 0.002) were signifi-
cantly lower in AMI patients than controls. 
 
Table 1: Clinical and demographic characteristics of AMI patients and controls 
Parameters AMI patients (n = 400) Controls (n = 150) p Value 
Age 59.07 ± 7.34 59.48 ± 7.73 0.57 a 
Gender, Female / Male 155 / 245 57 / 93 0.87 b 
Body mass index (kg/m2) 26.58 ± 3.95 25.77 ± 4.16 0.04 a 
Hemoglobin (g/mL) 13.46 ± 2.24 14.05 ± 2.14 0.01 a 
Hypertension, n (%) 172 (42%) 66 (44%) 0.83 b 
Diabetes, n (%) 98 (25%) 33 (22%) 0.54 b 
Smoking, n (%) 121 (30%) 42 (28%) 0.61 b 
Alcohol, n (%) 114 (29%) 38 (25%) 0.46 b 
Family History, n (%) 83 (21%) 31 (21%) 0.98 b 
a Independent sample t-tests,  b Chi-square test were used. 
 
Table 2: Mean levels of lipid profile and inflammatory markers in baseline serum sample of AMI pa-
tients and controls 
Parameters AMI patients (n = 400) Controls (n = 150) p Value 
TC (mg/dL) 174.81 ± 24.14 169.35 ± 16.34 0.003 
TG (mg/dL) 157.51 ± 45.67 149.65 ± 27.18 0.014 
LDL-C (mg/dL) 111.35 ± 25.81 105.55 ± 30.39 0.039 
HDL-C (mg/dL) 43.14 ± 11.34 49.21 ± 9.14 < 0.001 
TC / HDL-C 4.38 ± 1.42 3.57 ± 0.79 < 0.001 
LDL-C / HDL-C 2.82 ± 1.12 2.26 ± 0.83 < 0.001 
hs-CRP (mg/L) 9.82 ± 5.63 1.03 ± 0.67 < 0.001 
IL-6 (pg/mL) 50.80 ± 25.12 14.81 ± 6.65 < 0.001 
IL-10 (pg/mL) 11.65 ± 8.95 13.92 ± 6.06 0.002 
AMI; acute myocardial infarction, TC; total cholesterol, TG; triglyceride, LDL-C; low density lipoprotein cholesterol, HDL-
C; high density lipoprotein cholesterol, hs-CRP; high sensitive C-reactive protein, IL; interleukin. Values are in mean ± 
SD. Independent sample t-test was used. 
EXCLI Journal 2015;14:517-526 – ISSN 1611-2156 
Received: November 13, 2014, accepted: March 27, 2015, published: April 10, 2015 
 
 
521 
In AMI patients, all serum lipid levels 
changed significantly between day 1 post-MI 
(i.e., within 24 h) - day 7 post-MI (Table 3, 
Figure 1). From day 1 to day 2 post-MI, se-
rum TC levels (174.81 ± 24.14 vs. 161.68 ± 
30.77 mg/dL), LDL-C levels (111.35 ± 25.81 
vs. 102.28 ± 23.23 mg/dL), and HDL-C lev-
els (43.14 ± 11.34 vs. 36.78 ± 10.31 mg/dL) 
decreased significantly (p < 0.001). On the 
contrary, the serum TG levels increased sig-
nificantly (p < 0.001) from 157.51 ± 45.67 
on day 1 to 173.30 ± 48.79 mg/dL on day 2. 
Although, there were some improvements in 
lipid profile levels on day 7, they failed to 
reach the baseline levels. Laboratory find-
ings demonstrated there were significant 
fluctuations in the levels of inflammatory 
markers of AMI patients from day 1 - day 7 
(Figure 2). Serum levels of hs-CRP and IL-6 
that were measured at day 2 (17.70 ± 8.49 & 
66.99 ± 24.35) after AMI were significantly 
higher (p < 0.001) than at day 1 (9.82 ± 5.63 
& 50.80 ± 25.12) and day 7 (13.78 ± 7.54 & 
53.56 ± 25.77). On the other hand, anti-
inflammatory cytokine IL-10 levels seemed 
to increase from day 1 to day 2 (11.65 ± 8.95 
vs. 17.29 ± 13.54 pg/mL, p < 0.001) and to 
decrease again by day 7 (13.40 ± 10.97 
pg/mL) (Table 3). 
 
 
DISCUSSION 
A series of changes in lipid metabolism 
occur during acute phase response. As a re-
sult, plasma TG level increases, while HDL, 
LDL and TC levels decrease, demonstrated 
by many studies (Wattanasuwan et al., 
2001). There is no consensus with respect to 
timing of lipid and lipoprotein measurements 
in terms of proximity to the baseline values, 
the magnitude of the changes and when these 
changes reach maximum and basal values. A 
reduction in the magnitude of these changes 
is seen over time. First time Biorck et al. 
(1957) reported that serum cholesterol levels 
decreased during MI. Since then, a wide 
range of changes in the serum lipid and lipo-
proteins following acute coronary events 
have been reported. In the present study, we 
found significant changes in TC levels 
throughout the study period in AMI patients. 
There are several reports indicating that cho-
lesterol reduction takes place in the initial 
phase of an acute coronary event; thus, 
plasma levels determined at this point should 
be interpreted with caution. This reduction 
may be just a consequence of the inflamma-
tory response, or it may be related to an in-
crease in cellular uptake of cholesterol for 
tissue repair and hormonal synthesis (Correia 
Table 3: Comparison of serum lipid values and inflammatory markers between day 1, day 2 and day 7 
post- AMI 
Parameters Day1 Day 2 Day 7 
TC (mg/dL) 174.81 ± 24.14 161.68 ± 30.77 III 165.35 ± 32.25 c 
TG (mg/dL) 157.51 ± 45.67 173.30 ± 48.79 III 167.86 ± 48.84 b 
LDL-C (mg/dL) 111.35 ± 25.81 102.28 ± 23.23 III 103.26 ± 23.14 c 
HDL-C (mg/dL) 43.14 ± 11.34 36.78 ± 10.31 III 38.59 ± 11.48 c, * 
TC / HDL-C 4.38 ± 1.42 4.79 ± 1.72 II 4.71 ± 1.76 a 
LDL-C / HDL-C 2.82 ± 1.12 3.03 ± 1.15 I 2.95 ± 1.16 
hs-CRP (mg/L) 9.82 ± 5.63 17.70 ± 8.49 III 13.78 ± 7.54 c, # 
IL-6 (pg/mL) 50.80 ± 25.12 66.99 ± 24.35 III 53.56 ± 25.77 # 
IL-10 (pg/mL) 11.65 ± 8.95 17.29 ± 13.54 III 13.40 ± 10.97 # 
TC; total cholesterol, TG; triglycerides, LDL-C; low density lipoprotein cholesterol, HDL-C; high density lipoprotein cholesterol, 
hs-CRP; high sensitive C reactive protein, IL; Interleukin. Between day 1 and 2;  I p < 0.05,  II p < 0.01, and  III p < 0.001. Be-
tween day 1 and 3;  a p < 0.05,  b p < 0.01, and  c p < 0.001. Between day 2 and 3;  * p < 0.05,  # p < 0.001.One way ANOVA 
test, followed by Tukey’s post hoc test was used. 
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Figure 1: Mean levels of serum TC, TG, LDL-C, and HDL-C on Days 1, 2, and 7. TC; total cholesterol, 
TG; triglyceride, LDL-C; low density lipoprotein cholesterol, HDL-C; high density lipoprotein cholester-
ol, D; day 
 
et al., 2004). A previous report by Khan et 
al. (2013) showed significantly decreased 
level of TC in AMI patients. 
Results of this analysis also suggest that 
directly measured serum LDL-C after admis-
sion for an AMI changes in a statistically 
way from day 1 to day 7. During acute phase 
reaction, LDL synthesis is increased. Despite 
that, LDL level decreases due to up-regula-
tion of LDL-R activity (Balci, 2011). More-
over, LDL particle size is smaller in patients 
with AMI as compared to non-AMI patients. 
In addition, the decrease in LDL-C concen-
tration on day 2 of hospitalization may re-
flect causes related to hospitalization, such 
as altered oral intake or intravenous hydra-
tion (Pitt et al., 2008). Ko et al. (2005) in a 
large-scale review of patient records of ad-
missions for MI also found decreased LDL-
C between samples taken < 24 h (120 mg/ 
dL) and > 24 h (116 mg/dL) after admission. 
These results show agreement to the LATIN 
(Lipid Assessment Trial–Italian Network) 
study, where patients admitted within 12 h of 
symptom onset for MI or unstable angina 
found a mean 7 % (unstable angina) to 10 % 
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(MI) decrease from admission to the next 
day in direct-measured LDL-C that persisted 
until discharge (Fresco et al., 2002). 
HDL-C levels, in our study, started fall-
ing from day 2 onwards. Similar results were 
reported by Nigam (2007) and Kumar et al. 
(2009) in previous Indian studies. Rosoklija 
et al. (2004) concluded in their study that the 
optimal time for determining the HDL level 
were the first 24 hours of the actual event. In 
AMI, acute phase response has quantitative 
and qualitative effects on HDL and its con-
tents. Inflammation decreases the level of 
HDL by increasing the activity of endothelial 
lipase and soluble phospholipase A2 and re-
placing the apolipoprotein-A1 in the HDL 
with serum amyloid A. Moreover, inflamma-
tion leads to changes in the size and function 
of the HDL (Ansell et al., 2005). There is a 
decrease in the levels of several plasma pro-
teins included in HDL-mediated reverse 
transport of cholesterol and inhibition of li-
pid oxidation during inflammation. There-
fore, this remodeling creates functional alter-
ations, including a decrease in cholesterol ef-
flux capacity (Tsompanidi et al., 2010). TG 
levels were also significantly changed during 
the study period in the patient group.   
 
 
Figure 2: Mean levels of serum hs-CRP, IL-6 and IL-10 on days 1, 2, and 7. hs-CRP; high sensitive 
C-reactive protein, IL; interleukin, D; day, ns; non-significant 
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In some previous studies Nigam (2007) and 
Pitt et al. (2008) also reported an increased 
level of TG after AMI. Hypertriglyceridemia 
is caused by increased lipoprotein production 
and decreased lipoprotein clearance. Increase 
in TG-rich lipoproteins is secondary to the 
re-esterification of plasma fatty acids. Clear-
ance decreases mainly secondary to the inhi-
bition of lipoprotein lipase activity (Navab et 
al., 2009). Myocardial damage-induced 
stress increases the adrenergic-mediated li-
polysis of the adipocytes, which leads to an 
increase in free fatty acids, TGs and lipopro-
teins. The mobilization of free fatty acids 
and hepatic secretion of very low density 
lipoprotein also increases the TG levels 
(Balci, 2011). Based on these acute changes, 
the American College of Cardiolo-
gy/American Heart Association (ACC/AHA) 
have supported a Class I recommendation for 
a fasting lipid profile analysis to be obtained 
within 24 h of admission for ACS (acute 
coronary syndrome) (Anderson et al., 2007). 
As expected, levels of hs-CRP and IL-6 
were significantly higher in AMI patients as 
compared to the controls, and in patient’s 
group levels were increased from day 1 to 
day 2, and then decreased from day 2 to day 
7. In our patients, inflammatory markers lev-
el on day 2 were close to the peak of re-
sponse, representing that the inflammatory 
process associated with myocardial necrosis 
was still ongoing and at its height at our sec-
ond measurement. Similar results were 
shown by Yip et al. (2004), Sheikh et al. 
(2012) and Fan et al. (2011). AMI is a multi-
factorial disease, in which inflammatory pro-
cesses play a central role (Biswas et al., 
2010). In this regard, CRP and IL-6 are con-
sidered to be the most important markers and 
have been extensively studied in recent years 
(He et al., 2004; Tan et al., 2008). CRP 
might not only mirror an inflammatory stim-
ulus, but also have direct effects promoting 
atherosclerotic propagation and destabilizing 
plaque (Yip et al., 2004). Our finding sug-
gests that these substantially increased serum 
hs-CRP and IL-6 levels in the clinical setting 
of MI are due to the results of myocardial 
damage. Tissue necrosis is a potent acute-
phase stimulus, and following MI, there is a 
major CRP response, the magnitude of 
which reflects the extent of myocardial ne-
crosis (Pepys and Hirschfield, 2003). Plasma 
CRP concentration increases following the 
cytokines activation in the initial hours of 
MI. CRP binds to phosphocholine group of 
necrotic myocardial cell membranes, facili-
tating complement activation, and thus pro-
moting further inflammatory response, injury 
of myocardial cells, and expansion of necro-
sis (Swiatkiewicz et al., 2012). In some re-
cent studies, Khan et al. (2013) and Raposei-
ras Roubin et al. (2013) reported significant-
ly increased levels of hs-CRP in AMI pa-
tients. 
IL-6 is a pleiotropic cytokine with a 
broad range of humoral and cellular immune 
effects related to inflammation. Elevated IL-
6 levels may contribute to the development 
and instability of atherosclerotic plaques by 
activation of leukocytes and endothelial cells 
or by the induction of various cytokines 
(Shinohara et al., 2012). Furthermore, IL-6 
decreases lipoprotein lipase (LPL) activity 
and monomeric LPL levels in plasma, which 
increases macrophage uptake of lipids (Fan 
et al., 2011). In post-AMI patients, the acti-
vation of proinflammatory cytokines leads to 
high concentrations of inducible nitric oxide 
synthase, nitric oxide, and peroxynitrite, 
which have multiple harmful effects. In a re-
cent study, Lopez-Cuenca et al. (2013) re-
ported that high IL-6 on day 1 to be associat-
ed with poor long-term outcomes in MI pa-
tients, which reaffirms the prognostic signif-
icance of the proinflammatory status during 
the initial phase of an ACS. 
Consistent with some previous studies 
(Biswas et al., 2010), we found significant 
low levels of IL-10 in patients with AMI as 
compared to controls at day 1 serum sam-
ples. Less clinical data is available regarding 
the role of anti-inflammatory cytokines in 
AMI. It recently has been demonstrated that 
IL-10 may act as a protective factor in ather-
osclerosis and suppresses the synthesis of 
proinflammatory cytokines (Krishnamurthy 
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et al., 2009). Moreover, IL-10 is expressed in 
both early and advanced human atheroscle-
rotic plaques and inhibits many cellular pro-
cesses including metalloproteinase produc-
tion and tissue factor expression, which may 
play a role in the clinical expression of ath-
erosclerotic plaque rupture or erosion (Lako-
ski et al., 2008). Additionally, it may influ-
ence antigen presentation (including oxi-
dized lipids) from macrophages and dendrit-
ic cells, and even stabilize rupture prone 
plaques by suppressing apoptotic pathways 
in foam cells (Welsh et al., 2011). The 
mechanisms leading to increased release of 
IL-10 at day 2 in AMI patients remain un-
clear; however, it may be assumed that in 
severe inflammatory processes occurring in 
cardiovascular events, more IL-10 is pro-
duced as a compensatory phenomenon to in-
hibit continued pro-inflammatory cytokine 
production and inflammatory propagation, 
resulting in elevated levels of IL-10. Con-
sistent with this, circulating IL-10 is posi-
tively associated with IL-6 and hs-CRP 
(Welsh et al., 2011). 
In conclusion, the results indicate a trend 
of reduced TC, LDL-C, and HDL-C and ele-
vated TG levels along with inflammatory 
markers between day 1 and day 2 sample. 
However, corrections in the serum levels 
have been observed at day 7. Although the 
measurement of serum lipids is recommend-
ed after the admission of patients with ACS, 
serum lipid levels are measured in less than 
half of the patients. However, considering 
that phasic changes in serum lipid and lipo-
protein levels occur after 24 hours of ACS, 
the findings of this study emphasize the need 
for assessment of the lipid profile of these 
patients to be made at admission, so as to 
identify patients at a higher potential risk. 
Exact knowledge regarding baseline serum 
lipids and lipoprotein levels as well as their 
varying characteristics can be used to guide 
selection of lipid lowering medication. 
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